You are here: Industry Insights > Verzenio

News List

Verzenio Demonstrates Significant Improvement in Overall Survival in Breast Cancer Trial americanpharmaceuticalreview
August 01, 2019
Eli Lilly and Company announced Verzenio (abemaciclib) demonstrated a statistically significant improvement in overall survival in the Phase 3 MONARCH 2 clinical trial.
Health Canada approves new drug to treat metastatic breast cancer through international and domestic joint reviews firstwordpharma
April 10, 2019
OTTAWA, April 9, 2019 /CNW/ - Canadians want improved access to the most recent and innovative treatment options for themselves and their families.
Lilly Receives Additional FDA Approval for Verzenio Americanpharmaceuticalreview
February 28, 2018
Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved Verzenio (abemaciclib) in combination with an aromatase inhibitor (AI) ...
Lilly’s Verzenio misses key survival goal in lung cancer pharmatimes
October 12, 2017
Eli Lilly’s breast cancer drug Verzenio has failed to improve overall survival in a late-stage study assessing the drug’s potential in patients with KRAS-mutated, advanced non-small lung cancer (NSCLC).
FDA approves Verzenio for metastatic breast cancer europeanpharmaceuticalreview
September 30, 2017
The FDA has approved Verzenio to treat advanced or metastatic breast cancer that has progressed after taking therapy…